Dual-action cephalosporin utilizing a novel therapeutic principle.
A new cephalosporin is described that overcomes, in a novel way, the general susceptibility of this group of agents to enterobacterial beta-lactamases. The new compound carries a substituent that is released on cleavage of the beta-lactam ring and then exhibits antibacterial activity in its own right. The possible therapeutic benefits of such an antibiotic are discussed.
D000667:Ampicillin / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D003497:Cyclic N-Oxides / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D013438:Sulfhydryl Compounds / Q000494:pharmacology; D001745:Urinary Bladder Diseases / Q000188:drug therapy
D002511:Cephalosporins; D003497:Cyclic N-Oxides; D013438:Sulfhydryl Compounds; D000667:Ampicillin